WO2000066731A3 - Laminine 5 recombinee - Google Patents

Laminine 5 recombinee Download PDF

Info

Publication number
WO2000066731A3
WO2000066731A3 PCT/US2000/011459 US0011459W WO0066731A3 WO 2000066731 A3 WO2000066731 A3 WO 2000066731A3 US 0011459 W US0011459 W US 0011459W WO 0066731 A3 WO0066731 A3 WO 0066731A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant laminin
methods
laminin
recombinant
migration
Prior art date
Application number
PCT/US2000/011459
Other languages
English (en)
Other versions
WO2000066731A2 (fr
Inventor
Ariel Boutaud
Original Assignee
Biostatum Inc
Ariel Boutaud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostatum Inc, Ariel Boutaud filed Critical Biostatum Inc
Priority to EP00928524A priority Critical patent/EP1177290A2/fr
Priority to JP2000615755A priority patent/JP2002542824A/ja
Priority to AU46753/00A priority patent/AU4675300A/en
Publication of WO2000066731A2 publication Critical patent/WO2000066731A2/fr
Publication of WO2000066731A3 publication Critical patent/WO2000066731A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

L'invention concerne la laminine 5 recombinée, des procédés de fabrication de la laminine 5, des cellules exprimant la laminine 5 recombinée ainsi que des techniques d'utilisation de la laminine 5 recombinée pour accélérer la cicatrisation et pour favoriser la fixation et la migration des cellules.
PCT/US2000/011459 1999-04-30 2000-04-28 Laminine 5 recombinee WO2000066731A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00928524A EP1177290A2 (fr) 1999-04-30 2000-04-28 Laminine 5 recombinee
JP2000615755A JP2002542824A (ja) 1999-04-30 2000-04-28 組換えラミニン５
AU46753/00A AU4675300A (en) 1999-04-30 2000-04-28 Recombinant laminin 5

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13172099P 1999-04-30 1999-04-30
US60/131,720 1999-04-30
US14973899P 1999-08-21 1999-08-21
US60/149,738 1999-08-21
US15594599P 1999-09-24 1999-09-24
US60/155,945 1999-09-24

Publications (2)

Publication Number Publication Date
WO2000066731A2 WO2000066731A2 (fr) 2000-11-09
WO2000066731A3 true WO2000066731A3 (fr) 2001-06-28

Family

ID=27384196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011459 WO2000066731A2 (fr) 1999-04-30 2000-04-28 Laminine 5 recombinee

Country Status (4)

Country Link
EP (1) EP1177290A2 (fr)
JP (1) JP2002542824A (fr)
AU (1) AU4675300A (fr)
WO (1) WO2000066731A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050111A2 (fr) 2000-12-21 2002-06-27 Biostratum, Inc. Laminine 10 isolee
JP4798560B2 (ja) * 2003-06-04 2011-10-19 よこはまティーエルオー株式会社 ラミニン５ｂ
JP4566603B2 (ja) * 2004-03-31 2010-10-20 財団法人かずさディー・エヌ・エー研究所 細胞付着ポリペプチド
FR2873698B1 (fr) * 2004-07-29 2006-10-20 D Anjou Sa Lab Nouveau peptide et composition pharmaceutique le contenant
EP1853328A2 (fr) * 2005-02-23 2007-11-14 SurModics, Inc. Articles medicaux implantables a revetement de laminine et methodes d'utilisation
FR2943062B1 (fr) * 2009-03-13 2011-04-08 Symatese Nouveau peptide promoteur de l'adhesion et de la migration cellulaire
JP6470286B2 (ja) 2013-11-27 2019-02-13 京都府公立大学法人 ラミニンの角膜内皮細胞培養への応用
US11633477B2 (en) 2014-10-31 2023-04-25 Kyoto Prefectural Public University Corporation Treatment of cornea using laminin
JP6770435B2 (ja) 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
JP6792852B2 (ja) * 2016-06-07 2020-12-02 国立大学法人 岡山大学 角化歯肉誘導剤
WO2018203834A1 (fr) * 2017-05-05 2018-11-08 National University Of Singapore Procédés de culture de kératinocytes humains
FR3127219A1 (fr) 2021-09-20 2023-03-24 Laboratoires D'anjou Nouveaux peptides et compositions pharmaceutiques et cosmetiques les contenants

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204302A2 (fr) * 1985-06-03 1986-12-10 Meloy Laboratories, Inc. Laminine et sa préparation
WO1994005316A1 (fr) * 1992-08-28 1994-03-17 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Produits et procedes destines a ameliorer l'adhesion du keratinocyte sur le derme
WO1995011972A1 (fr) * 1993-10-27 1995-05-04 The General Hospital Corporation CHAINE B1k DE LAMININE ET PROCEDES D'UTILISATION
WO1995013103A2 (fr) * 1993-11-12 1995-05-18 Desmos, Inc. Stimulation par facteurs solubles de la fixation et de l'assemblage d'hemidesmosomes dans les cellules epitheliales
WO1996010646A1 (fr) * 1994-10-04 1996-04-11 Karl Tryggvason Chaines de laminine: utilisation diagnostique et therapeutique
WO1997012961A2 (fr) * 1995-10-06 1997-04-10 Desmos, Inc. Augmentation du nombre de cellules adultes des ilots de langerhans du pancreas, a l'aide de laminine-5
WO1997036621A1 (fr) * 1996-03-29 1997-10-09 Desmos, Inc. Fixation de cellules sur des dispositifs trans-epitheliaux recouverts de laminine 5
WO1997047652A1 (fr) * 1996-06-10 1997-12-18 Desmos, Inc. Purification de laminine soluble de type 5
WO1997048415A1 (fr) * 1996-06-05 1997-12-24 The General Hospital Corporation Laminine-5 et formation d'une structure de membrane basale
WO1998011217A2 (fr) * 1996-09-13 1998-03-19 Sagami Chemical Research Center Proteines humaines comportant des sequences de signaux secretoires et adn codant ces proteines

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204302A2 (fr) * 1985-06-03 1986-12-10 Meloy Laboratories, Inc. Laminine et sa préparation
WO1994005316A1 (fr) * 1992-08-28 1994-03-17 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Produits et procedes destines a ameliorer l'adhesion du keratinocyte sur le derme
WO1995011972A1 (fr) * 1993-10-27 1995-05-04 The General Hospital Corporation CHAINE B1k DE LAMININE ET PROCEDES D'UTILISATION
WO1995013103A2 (fr) * 1993-11-12 1995-05-18 Desmos, Inc. Stimulation par facteurs solubles de la fixation et de l'assemblage d'hemidesmosomes dans les cellules epitheliales
WO1996010646A1 (fr) * 1994-10-04 1996-04-11 Karl Tryggvason Chaines de laminine: utilisation diagnostique et therapeutique
WO1997012961A2 (fr) * 1995-10-06 1997-04-10 Desmos, Inc. Augmentation du nombre de cellules adultes des ilots de langerhans du pancreas, a l'aide de laminine-5
WO1997036621A1 (fr) * 1996-03-29 1997-10-09 Desmos, Inc. Fixation de cellules sur des dispositifs trans-epitheliaux recouverts de laminine 5
WO1997048415A1 (fr) * 1996-06-05 1997-12-24 The General Hospital Corporation Laminine-5 et formation d'une structure de membrane basale
WO1997047652A1 (fr) * 1996-06-10 1997-12-18 Desmos, Inc. Purification de laminine soluble de type 5
WO1998011217A2 (fr) * 1996-09-13 1998-03-19 Sagami Chemical Research Center Proteines humaines comportant des sequences de signaux secretoires et adn codant ces proteines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAGNOUX-PALACIOS L ET AL: "Functional re-expression of laminin-5 in laminin-gamma2-deficient human keratinocytes modifies cell morphology, motility, and adhesion", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 271, no. 21, 2 August 1996 (1996-08-02), pages 18437 - 18444, XP002154950 *
MATSUI C ET AL: "The assembly of laminin-5 subunits", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 270, no. 40, 6 October 1995 (1995-10-06), pages 23496 - 23503, XP002154951 *
NICOSIA R ET AL: "Modulation of angiogenesis in vitro by laminin-entactin complex", DEV BIOL, vol. 164, no. 1, July 1994 (1994-07-01), pages 197 - 206, XP000971040 *
VAILLY J ET AL: "Corrective gene transfer of keratinocytes from patients with junctional epidermolysis bullosa restores assembly of hemidesmosomes in reconstructed epithelia", GENE THER., vol. 5, no. 10, October 1998 (1998-10-01), pages 1322 - 1332, XP000961159 *

Also Published As

Publication number Publication date
WO2000066731A2 (fr) 2000-11-09
JP2002542824A (ja) 2002-12-17
EP1177290A2 (fr) 2002-02-06
AU4675300A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
WO2000066730A3 (fr) Laminine 2 et ses methodes d'utilisation
IL144654A0 (en) Pancreatic progenitor cells, methods and uses related thereto
IL147803A0 (en) 28-epirapalogs
ZA965381B (en) Electrochemical cell.
AU5850200A (en) Positive plate active material, method for producing the same, and secondary cell
EP1024502A4 (fr) Composition d'electrolyte, electrolyte et son procede de production, et cellule contenant ceux-ci
ZA978256B (en) Electrolyte.
AU2748201A (en) Graft polymerization, separators, and batteries including the separators
MXPA01005732A (es) Triterpenos pentaciclicos.
HK1045763A1 (en) Fuel assembly and method for use with the fuel cell assembly.
HK1005962A1 (en) Alkaline cell and the preparation thereof.
EP0682107A3 (fr) Procédé pour la culture à long terme de cellules de la papille dermale.
WO1999045098A3 (fr) Apport de proteines a des cellules eucaryotes au moyen de la yersinia recombinee
WO2000066731A3 (fr) Laminine 5 recombinee
GR3032605T3 (en) Sugar-modified cytostatics
ZA971182B (en) Electrochemical cell.
AU1741601A (en) Mesenchymal stem cells and/or progenitor cells, their isolation and use
EP0681339A3 (fr) Cellule électrochimique.
GB2355579A8 (en) Molded electrode, method for production thereof, and secondary battery using the electrode
MXPA01011816A (es) Rejilla de bateria y metodo para fabricarla.
AU4423799A (en) Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
WO2000066732A3 (fr) Laminine 8 et ses procedes d'utilisation
AU673414B2 (en) Cathodic active material composition for dry cells, method for preparing the same, and alkaline battery
ZA9810371B (en) Th2 cell depletion; compositions; methods.
PL354994A1 (en) Bio-supportive matrices, methods of making and using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 615755

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000928524

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928524

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000928524

Country of ref document: EP